Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
5 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
Salvage therapy expands highly cytotoxic and metabolically fit resilient CD8+ T cells via ME1 up-regulation.
Sci Adv. 2023 Nov 17;9(46):eadi2414. doi: 10.1126/sciadv.adi2414. Epub 2023 Nov 15.
Sci Adv. 2023.
PMID: 37967193
Free PMC article.
A Novel PD-L1 Antibody Promotes Antitumor Function of Peripheral Cytotoxic Lymphocytes after Radical Nephrectomy in Patients with Renal Cell Carcinoma.
An Z, Hsu MA, Gicobi JK, Xu T, Harrington SM, Zhang H, Pavelko KD, Hirdler JB, Lohse CM, Nabavizadeh R, Pessoa RR, Sharma V, Thompson RH, Leibovich BC, Dong H, Lucien F.
An Z, et al. Among authors: hirdler jb.
J Immunol. 2023 Jun 15;210(12):2029-2037. doi: 10.4049/jimmunol.2200933.
J Immunol. 2023.
PMID: 37163328
Item in Clipboard
A Novel Humanized PD-1/PD-L1 Mouse Model Permits Direct Comparison of Antitumor Immunity Generated by Food and Drug Administration-Approved PD-1 and PD-L1 Inhibitors.
Barham W, Hsu M, Liu X, Harrington SM, Hirdler JB, Gicobi JK, Zhu X, Zeng H, Pavelko KD, Yan Y, Mansfield AS, Dong H.
Barham W, et al. Among authors: hirdler jb.
Immunohorizons. 2023 Jan 1;7(1):125-139. doi: 10.4049/immunohorizons.2200054.
Immunohorizons. 2023.
PMID: 36656137
Free PMC article.
Item in Clipboard
Understanding Suboptimal Response to Immune Checkpoint Inhibitors.
Zhu M, Zhang H, Pedersen KS, Foster NR, Jaszewski BL, Liu X, Hirdler JB, An Z, Bekaii-Saab TS, Halfdanarson TR, Boland PM, Yan Y, Hubbard JH, Ma WW, Yoon HH, Revzin A, Fernandez-Zapico ME, Overman MJ, McWilliams RR, Dong H.
Zhu M, et al. Among authors: hirdler jb.
Adv Biol (Weinh). 2023 Apr;7(4):e2101319. doi: 10.1002/adbi.202101319. Epub 2022 Mar 27.
Adv Biol (Weinh). 2023.
PMID: 35343107
Item in Clipboard
NKG7 Is a T-cell-Intrinsic Therapeutic Target for Improving Antitumor Cytotoxicity and Cancer Immunotherapy.
Wen T, Barham W, Li Y, Zhang H, Gicobi JK, Hirdler JB, Liu X, Ham H, Peterson Martinez KE, Lucien F, Lavoie RR, Li H, Correia C, Monie DD, An Z, Harrington SM, Wu X, Guo R, Dronca RS, Mansfield AS, Yan Y, Markovic SN, Park SS, Sun J, Qin H, Liu MC, Vasmatzis G, Billadeau DD, Dong H.
Wen T, et al. Among authors: hirdler jb.
Cancer Immunol Res. 2022 Feb;10(2):162-181. doi: 10.1158/2326-6066.CIR-21-0539. Epub 2021 Dec 15.
Cancer Immunol Res. 2022.
PMID: 34911739
Free PMC article.
Item in Clipboard
Cite
Cite